Retatrutide
Also referred to as: LY3437943, GGG tri-agonist
An experimental peptide built to hit three different metabolic targets at once. Studied in clinical trials in connection with blood sugar and weight and fat loss.
In plain terms: Retatrutide is an experimental drug, still being tested, that is designed to act on three of the body's metabolic "switches" at the same time. Researchers are studying it mainly around blood sugar control and weight and fat loss. It has been tested in people in clinical trials, but it is not an approved medicine.
- Name
- Retatrutide
- Aliases
- LY3437943, GGG tri-agonist
- Classification
- Triple receptor agonist (peptide)
- Areas studied
- GIP/GLP-1/glucagon, Metabolic research, Receptor signaling
What it is
Retatrutide is an experimental lab-made peptide designed to act on three of the body's metabolic targets at once — receptors called GIP, GLP-1, and glucagon. (Receptors are the "docking points" on cells that hormones plug into to send a signal.) It is part of a research effort into drugs that hit several targets with a single molecule.
It has been tested in registered clinical trials in people. As an experimental compound, it is not an approved medicine.
Mechanism
Retatrutide is built to plug into three receptors that all play a role in metabolism — how the body handles blood sugar, hunger, and energy. The idea behind hitting all three at once is to study whether the combined effect is more useful than targeting just one.
Researchers are studying how switching on all three of these pathways together affects the body's metabolism, including in connection with weight and fat loss.
Areas studied & investigated
The categories below summarize where Retatrutide appears in the research literature. They describe what the compound is studied for and investigated in — not approved uses, and not guidance for any kind of use.
Blood sugar & hunger signals
Studied for how it acts on the GIP and GLP-1 pathways, which help control blood sugar and appetite.
Glucagon pathway
Adds a third target (glucagon) that many similar drugs do not, which is part of what makes it of research interest.
Weight & fat loss
Studied in clinical trials in connection with body weight and fat loss.
Multi-target drug design
A leading research example of one molecule built to act on several targets at once.
Research history
Retatrutide came out of drug research into multi-target peptides that build on earlier single- and dual-target compounds. It entered registered clinical trials in the early 2020s, with results published in major medical journals.
State of the literature
Retatrutide has been studied in registered human clinical trials, with results published in major journals. It is still experimental and not approved. Research is ongoing.
What to keep in mind
Retatrutide has more human data behind it than most peptides on this site, which is genuinely notable — but "in clinical trials" is not the same as "approved and proven safe for general use." Trials are how safety and effects get measured, and that process is not finished here. Treat the published trial results as the real evidence, and be skeptical of anyone presenting an experimental compound as if it were a settled product.
Research tools
Evaluating a Retatrutide batch for laboratory research? These free, research-use-only calculators help you work the numbers and read the paperwork: the reconstitution calculator solves vial concentration and draw volume, and the COA reader walks a certificate line by line. For how much and how often Retatrutide is commonly used, see the dosing guides.
Batch-tested with published COAs
See a published COA for Retatrutide
Midwest Compounds sells Retatrutide with a batch-linked certificate of analysis from an independent lab, published before you buy. This page is educational; purchasing happens on the store.
Citations
The summary above is drawn from published, peer-reviewed sources. Links open the abstract on PubMed, or the free full text on PubMed Central (PMC) where marked.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. Abstract
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022. Abstract